Cara Therapeutics Files 8-K on Shareholder Votes and Financials
Ticker: TVRD · Form: 8-K · Filed: Jun 7, 2024 · CIK: 1346830
| Field | Detail |
|---|---|
| Company | Cara Therapeutics, Inc. (TVRD) |
| Form Type | 8-K |
| Filed Date | Jun 7, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, financial-reporting, regulatory-filing
TL;DR
Cara Therapeutics filed an 8-K detailing shareholder votes and financial statements as of June 4, 2024.
AI Summary
Cara Therapeutics, Inc. filed an 8-K on June 7, 2024, reporting on matters submitted to a vote of security holders and financial statements as of June 4, 2024. The filing indicates changes to the company's articles of incorporation or bylaws and includes exhibits.
Why It Matters
This filing provides updates on corporate governance and financial reporting, which are crucial for investors to assess the company's current standing and future direction.
Risk Assessment
Risk Level: low — This is a routine filing reporting on corporate actions and financial statements, not indicating any immediate operational or financial distress.
Key Players & Entities
- Cara Therapeutics, Inc. (company) — Registrant
- June 4, 2024 (date) — Date of earliest event reported
- June 7, 2024 (date) — Filing date
- Delaware (jurisdiction) — State of incorporation
- Stamford, Connecticut (location) — Principal executive offices
FAQ
What specific matters were submitted to a vote of security holders?
The filing indicates that matters were submitted to a vote of security holders, but the specific details of these matters are not elaborated upon in the provided text.
What is the significance of the 'Amendments to Articles of Incorporation or Bylaws' item?
This item signifies that Cara Therapeutics, Inc. has made or is reporting on changes to its foundational corporate documents, which could affect its governance structure or operational rules.
What period do the financial statements cover?
The filing mentions 'Financial Statements and Exhibits' and the 'Date as of Change' is June 4, 2024, suggesting the financial statements are current as of or around this date.
What is the company's primary industry?
Cara Therapeutics, Inc. is in the 'PHARMACEUTICAL PREPARATIONS' industry, with SIC code 2834.
When was Cara Therapeutics, Inc. incorporated?
The company was incorporated in Delaware, as indicated by the filing.
Filing Stats: 935 words · 4 min read · ~3 pages · Grade level 13.3 · Accepted 2024-06-07 16:05:20
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share CARA The Nasdaq Stock Marke
Filing Documents
- tm2416682d1_8k.htm (8-K) — 42KB
- tm2416682d1_ex3-1.htm (EX-3.1) — 8KB
- 0001104659-24-069625.txt ( ) — 225KB
- cara-20240604.xsd (EX-101.SCH) — 3KB
- cara-20240604_lab.xml (EX-101.LAB) — 33KB
- cara-20240604_pre.xml (EX-101.PRE) — 22KB
- tm2416682d1_8k_htm.xml (XML) — 4KB
03
Item 5.03 Amendments to Articles of Incorporation or Bylaws. Amendment of Certificate of Incorporation On June 7, 2024, Cara Therapeutics, Inc. (the "Company") filed a Certificate of Amendment to its Certificate of Incorporation (the "Certificate") with the Secretary of State of the shares of common stock of the Company from 100,000,000 shares to 200,000,000 shares. The Certificate is attached hereto as Exhibit 3.1 and is incorporated herein by reference.
07
Item 5.07 Submission of Matters to a Vote of Security Holders. On June 4, 2024, the Company held its Annual Meeting of Stockholders ("Annual Meeting"). At the Annual Meeting, the Company's stockholders voted on the five proposals set forth below. A more detailed description of each proposal is set forth in the Company's Proxy Statement filed with the Securities and Exchange Commission on April 22, 2024. Proposal 1 - Election of Directors Dr. Susan Shiff and Ms. Helen M. Boudreau were each elected to serve as a director of the Company's Board of Directors until the 2027 Annual Meeting of Stockholders and until their successor is duly elected or until their earlier resignation or removal, by the following votes: Nominee Votes For Votes Withheld Broker Non-Votes Susan Shiff, Ph.D. 20,753,354 6,256,188 12,814,548 Helen M. Boudreau 26,317,774 691,768 12,814,548 Proposal 2 - Approval, on a Non-Binding Advisory Basis, of the Compensation of the Company's Named Executive Officers The stockholders approved, on a non-binding advisory basis, the compensation of the Company's named executive officers, by the following votes: Votes For Votes Against Abstentions Broker Non-Votes 16,277,985 10,660,228 71,329 12,814,548 Proposal 3 - Ratification of the Selection of Independent Registered Public Accounting Firm The stockholders ratified the selection by the Audit Committee of the Board of Directors of the Company of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2024, by the following votes: Votes For Votes Against Abstentions Broker Non-Votes 39,560,082 188,261 75,747 0 Proposal No. 4 – Increase the Authorized Shares of Common Stock The stockholders approved the amendment of the Company's Certificate of Incorporation to increase the authorized number of shares of common stock from 100,000,000 to 200,000,000, by the following votes: Votes For Votes Against Abstenti
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 3.1 Certificate of Amendment to Certificate of Incorporation of Cara Therapeutics, Inc. 104 Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CARA THERAPEUTICS, INC. By: /s/ RYAN MAYNARD Ryan Maynard Chief Financial Officer (Principal Financial and Accounting Officer) Date: June 7, 2024